FDA Plans Osteoporosis Guidance Update
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is seeking comments to update a guidance on development of products for postmenopausal osteoporosis
You may also be interested in...
Pfizer/Ligand's Lasofoxifene Is First "Next-Generation" SERM Filed At FDA
NDA for the selective estrogen receptor modulator has an estimated user fee date of June 2005 for post-menopausal osteoporosis prevention indication. Drug could offer benefits over Lilly's SERM Evista, Ligand says.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.